Takeda Pharmaceutical (NYSE:TAK) Upgraded to “Outperform” at Sanford C. Bernstein

Takeda Pharmaceutical (NYSE:TAK) was upgraded by equities researchers at Sanford C. Bernstein from a “market perform” rating to an “outperform” rating in a report issued on Wednesday, MarketBeat.com reports.

Other equities analysts have also recently issued research reports about the stock. Morgan Stanley began coverage on shares of Takeda Pharmaceutical in a research note on Tuesday, January 13th. They issued an “overweight” rating for the company. Wall Street Zen cut shares of Takeda Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 21st. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Stock Performance

Takeda Pharmaceutical stock traded up $0.45 during mid-day trading on Wednesday, reaching $18.74. The company had a trading volume of 421,682 shares, compared to its average volume of 2,996,342. The company has a quick ratio of 0.65, a current ratio of 1.19 and a debt-to-equity ratio of 0.56. Takeda Pharmaceutical has a 52 week low of $12.99 and a 52 week high of $18.90. The company has a 50 day moving average of $18.13 and a 200-day moving average of $15.93. The firm has a market cap of $59.62 billion, a price-to-earnings ratio of 78.11 and a beta of -0.01.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Friday, January 30th. The company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.07). Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. The company had revenue of $7.60 billion during the quarter, compared to the consensus estimate of $7.81 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.160-3.160 EPS. On average, sell-side analysts expect that Takeda Pharmaceutical will post 1.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Takeda Pharmaceutical

A number of hedge funds have recently made changes to their positions in the company. Valeo Financial Advisors LLC increased its position in shares of Takeda Pharmaceutical by 6.0% during the 4th quarter. Valeo Financial Advisors LLC now owns 11,220 shares of the company’s stock worth $175,000 after purchasing an additional 632 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Takeda Pharmaceutical by 3.8% during the 3rd quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock worth $285,000 after purchasing an additional 713 shares in the last quarter. Private Trust Co. NA increased its position in shares of Takeda Pharmaceutical by 84.7% during the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after purchasing an additional 783 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Takeda Pharmaceutical by 5.3% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 16,927 shares of the company’s stock worth $248,000 after purchasing an additional 850 shares in the last quarter. Finally, Sanctuary Advisors LLC increased its position in shares of Takeda Pharmaceutical by 4.0% during the 4th quarter. Sanctuary Advisors LLC now owns 23,626 shares of the company’s stock worth $368,000 after purchasing an additional 912 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.